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available at the end of the articleUse of p-values is widespread in the sciences, especially so in biomedical research, and
also underlies several analytic approaches in data mining. Its original intent is simple
enough, but its application and interpretation are far from simple. If data is collected
to evaluate an idea, a hypothesis, then accepting the idea, when it is true, is a good
thing, and rejecting the idea when it is not true, is also good. Two errors in reasoning
from the data then can occur: a true idea is rejected (making a Type I error), or a false
idea is accepted (Type II error).
However, simple criticisms and essential distinctions are immediate: (1) The p-value
is not a probability of an idea being true; such a more evolved statement requires using
Bayes theorem—at least—and a different frame for inference; (2) Just stating the result
of a statistical test as a p-value is nearly uninformative, as a statistically significant
outcome may have no practical biological importance; and continuing (3) The size of
the departure from the proposed true idea, the effect size, could be quite small in the
subject matter context; (4) The statistical method chosen for making a p-value
declaration could be doubtful, or inappropriate (i.e. wrong); (5) The consequences of
reasoning forward from a declared p-value has uneven consequences: so-called false
positive and false negatives are rampant and often hard to reckon with in many biomedical
testing environments (e.g. mammograms); all of which to say is (6) The utility or cost of
false positives and false negatives is unexamined in simple p-value declarations.
All the above is well-known in the statistical community and much-studied over
many years [1,2]. More recent problems with p-values include: (1) Correction for mul-
tiple testing, over hundreds, thousands or even millions of tests, using methods such
as Bonferroni or False Discovery Rate (FDR). This occurs often in genomics and data
mining and the corrections, or adjustments are often scientifically ungrounded and as-
sume the universal null hypothesis that all findings are due to chance [3]. The central
problem is that such testing assumes the separate p-values are in effect, independent
agents, and the power to detect biological associations from one gene or genetic vari-
ant to the next are sent to zero. Introducing biologically realistic entanglements and
higher order correlations across genomic sites and events is deeply problematic and
nearly impossible to get right; (2) Another problem is that the reported p-values of
such tests of association are weirdly at odds with current basic science. Consider, for
example, quantum mechanics that is the single most experimentally well-validated
understanding of basic physics ever proposed in the history of science. Despite its
scientific rigor, quantum mechanics is accurate only to about eight or nine significant
digits. However, it is not uncommon for researchers to report p-values of less than
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decay rate of the proton.
Further, such small p-values cannot be justified by randomization or statistically
grounded arguments given the relatively small sample sizes in play. They only
announce a blind faith in the validity of an assumed distribution (like the chi-squared)
for parsing an observed test outcome far into its tail.
A problem closely related to the strict reliance on p-values—and the two kinds of
errors, the false negatives and positives—is the wide use of Receiver Operator Curves
(ROC) curves. This scheme arose in the 1940s for testing the performance of a radio
receiver and for that kind of device good reception across an entire bandwidth makes
sense. So the device needs to have low reception error and high rejection of noise at
many frequencies. For a medical test this usually makes no sense: The researcher makes
a practical and scientific decision about applying the test (setting the threshold), and
proceeds to use the test accordingly on the next patient. But the patient is not a radio
under test. Next, the area under the ROC curve, the AUC value, is thought useful and
often reported as determinative. However, it is easy to construct simple and plausible
examples where the AUC estimate is unstable with multiple test outcomes all having
AUC exactly equal to 1, and all being distinct in terms of inference.
So, given all the problems above, what good purpose is served, or could be served by
p-values? This can be resolved by bringing the focus back to the scientific, data mining
questions: What are the hypotheses of interest (are there different ways to frame the
analysis)? Are the hypotheses under study related in some way (independent, not inde-
pendent)? What are the costs of drawing the wrong conclusion (what at the underlying
risks, estimated effect sizes)? Beyond p-values, FDR, ROC, and AUC, are there more
efficient uses of the same data? What is truly predictive rather than being merely
significant? This last question is, indeed, the single most critical and drives an informed
and grounded response to all the others. We will explore these entangled issues in
future editorials.
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